Arras Hospital
Arras, France, 62000
NCT Number: NCT06562725
Fiberoptic bronchoscopy (FOB) can cause a significant increase in respiratory resistances and airway pressure during mechanical ventilation (MV), which can jeopardize the delivery of the ventilatory assistance. This randomized controlled study tests the hypothesis that new ventilator settings aimed at reducing airway pressure may facilitate FOB during MV. Results of this trial should lead to propose a new ventilatory strategy for critically ill patients needing a FOB procedure under MV.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Arras, France, 62000
Introduction : Fiberoptic bronchoscopy (FOB) during mechanical ventilation (MV) is a challenging procedure as it considerably reduces the endotracheal tube internal diameter, increasing respiratory resistances, which may compromise the delivering of the ventilatory assistance. According to respiratory physiology principles applied to MV, the reduction of inspiratory flow and tidal volume are likely to reduce airway pressure during the inspiratory phase when respiratory resistances increase. Based on this assumption, we propose new ventilator settings aimed at reducing airway pressure during FOB. This study represents the first investigation to test special ventilator settings in order to facilitate FOB during MV.
Methods and analysis : This is a single-center randomized controlled trial, in which intubated patients undergoing a FOB will be assigned (1/1) either to receive the new ventilatory strategy or to stay on the ventilator settings previously selected by the attending physician. The intervention group will be applied the specific ventilator settings (inspiratory flow <25 L/min, tidal volume = 5 mL/Kg, inspiratory time = 1 sec, respiratory frequency <20c/min, positive end expiratory pressure(PEEP) = 5 cmH2O). The primary endpoint will be the reduction of the occurrence of a serious adverse event - inability to deliver the ventilatory support, significant arterial desaturation, or hemodynamics instability - during FOB prompting the interruption of the procedure. The sample size was estimated at a minimum of 46 patients to demonstrate a 50% reduction in the occurrence of such a serious adverse event with a power of 90% and an alpha risk of 0.05 (paired Student t-test).
An adjudication committee evaluates images (scope and monitor) to validate primary endpoint. This is done blinding randomization group.
Results of this trial should lead to propose a new ventilatory strategy for critically ill patients needing a FOB procedure under MV.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The special ventilator settings used in the intervention group - aimed at reducing airway pressure - include inspiratory flow <25 L/min, tidal volume = 5m L/Kg, inspiratory time = 1 sec, respiratory frequency <20 c/min, PEEP = 5 cmH2O, and FiO2 = 100%
Time frame: 5 minutes after bronchoscopy initiation
Occurrence of a serious adverse - ventilatory, respiratory, or circulatory - event prompting the procedure to be interrupted early in the first 5 minutes.
Time frame: 5 minutes after bronchoscopy initiation
Significant reduction in minute ventilation during FOB compared to its initial value
Time frame: 5 minutes after bronchoscopy initiation
Significant decrease in the "partial pressure of oxygen in arterial blood (PaO2)"/FiO2 ratio during FOB compared to its initial value
Time frame: 5 minutes after bronchoscopy initiation
Significant increase in PaCO2 during FOB compared to its initial value
Time frame: 5 minutes after bronchoscopy initiation
Significant reduction in episodes of tachycardia, arrythmia, or circulatory instability occurring during the procedure
Centre Hospitalier Arras
Other
Acronym: VentSetFib
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06019078
Agnosia, Analgesia
Abbotsford British Columbia, British Columbia, Canada
View Trial DetailsNCT01948635
Critical Illness, Cross Infection
Lille, Nord, France
View Trial DetailsNCT05591950
Critical Illness, Disease Attributes
Berlin, State of Berlin, Germany
View Trial DetailsNCT03972384
Cognition Disorders, Cognitive Dysfunction
Columbus, Ohio, United States
View Trial Details